Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

NCT04773782 is registered in ClinicalTrials.gov with Blueprint Medicines Corporation as lead sponsor.

NCT NCT04773782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04773782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
Lead sponsor
Blueprint Medicines Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
February 24, 2022
Completion date
November 21, 2025
Enrollment
29 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

cns tumor, relapsed solid neoplasm, solid tumor, unspecified, child